We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » 340B Program Lacks Price Transparency, Federal Watchdogs Tell HELP Committee
340B Program Lacks Price Transparency, Federal Watchdogs Tell HELP Committee
Gauging the 340B drug discount program’s effectiveness requires more price transparency and clearer guidance, expert witnesses told the Senate health committee Tuesday.